DISTRIBUTION AGREEMENTDistribution Agreement • April 9th, 2021 • Valneva SE • Biological products, (no disgnostic substances)
THIS DISTRIBUTION AGREEMENT (“Agreement”) is entered into as of December 9, 2015, between VALNEVA AUSTRIA GMBH, CIN: FN 389960 x, organized under the laws of Austria, with its registered office at Campus Vienna Biocenter 3, AT-1030 Vienna, Austria, hereinafter referred to as “SUPPLIER”, and GLAXOSMITHKLINE GMBH & CO. KG, organized under the laws of Germany, with its registered office at Prinzregentenplatz 9, D-81675 Munich, Germany, hereinafter referred to as “DISTRIBUTOR,” (hereinafter each referred to as a “Party”, and collectively as the “Parties”).
SUBLICENSE AGREEMENTSublicense Agreement • April 9th, 2021 • Valneva SE • Biological products, (no disgnostic substances) • New York
This SUBLICENSE AGREEMENT (the “Agreement”) is made and executed as of April 14, 2003 (the “Effective Date”) by and between InterCell Biomedical Research and Development AG, having its principal place of business at Campus Vienna Biocenter 6, A-1030, Vienna, Austria (hereinafter “InterCell”) and VaccGen International, LLC, having its principal place of business at 8 Cambridge Court, Larchmont, New York 10538, U.S.A. (hereinafter “VaccGen”).
SUPPLY AGREEMENT - Vaccine against Japanese encephalitis virus by and among INTERCELL AG and VETTER PHARMA-FERTIGUNG GMBH & CO. KG And INTERCELL BIOMEDICAL LTD. dated as of March 1, 2008Supply Agreement • April 9th, 2021 • Valneva SE • Biological products, (no disgnostic substances)
THIS COMMERCIAL SUPPLY AGREEMENT, made and entered into as of this 1st day of March, 2008 (hereinafter referred to as the “Agreement”), by and among Intercell Biomedical Ltd., a company registered in Scotland under the Companies Act of 1985 with registered number SC 260350, having its registered office at 30-31 Queen Street, Edinburgh, Scotland (“Intercell”), Intercell AG, a company duly organized and existing under the laws of Austria, having its principal place of business located at Campus Vienna Biocenter 2, 1030 Vienna, Austria, FB-NR. 166438 M/HG Wien, in its capacity as parent company guarantor (“Intercell AG”), and Vetter Pharma-Fertigung GmbH & Co. KG, a company duly organized and existing under the laws of Germany, having its principal place of business at Schützenstraße 87, 88212 Ravensburg, Germany (“Vetter”) Intercell and Vetter hereinafter individually also referred to as “Party” and collectively as the “Parties”,
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) CUSTOMARILY AND ACTUALLY TREATED BY THE REGISTRANT AS PRIVATE OR CONFIDENTIAL.Amendment Agreement • April 9th, 2021 • Valneva SE • Biological products, (no disgnostic substances)
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between PFIZER INC. and VALNEVA AUSTRIA GMBH April 29, 2020Collaboration and License Agreement • April 9th, 2021 • Valneva SE • Biological products, (no disgnostic substances) • New York
Each of the Development Payments set forth above will be payable one time only (regardless of the number of Products with respect to which, or the number of times with respect to any Product, the specified Development Event occurs). No Development Payments will be payable by Pfizer for any subsequent Product regardless of the number of Products Developed. For clarification, if one Product replaces another Product in Development, then such replacement Product will only be subject to Development Payments that have not previously been triggered by one or more prior Products. The maximum amount payable by Pfizer under this Agreement with respect to all Development Payments if all Development Events occur will be one hundred seventy-eight million dollars ($178,000,000).
